Surgical intervention and anesthetic management of the patient with Parkinson's disease

International Anesthesiology Clinics

Volumn 34, Issue 4, 1996, Pages 133-150

  Mason, Linda J ^a   Cojocaru, Traian T ^a   Cole, Daniel J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE DIMALEATE; AMANTADINE; AMOXAPINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BENZATROPINE MESILATE; BIPERIDEN; BROMOCRIPTINE MESILATE; BUSPIRONE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; FENTANYL; FENTANYL CITRATE; GASTROINTESTINAL AGENT; HYOSCYAMINE; INHALATION ANESTHETIC AGENT; LEVODOPA; LEVSINEX; LITHIUM; LITHIUM CARBONATE; METHYLDOPA; NEUROLEPTIC AGENT; PERGOLIDE MESILATE; PETHIDINE; PROCYCLIDINE; RESCINNAMINE; SELEGILINE; SUFENTANIL; SUFENTANIL CITRATE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; HUMAN; INHALATION ANESTHESIA; INHALATIONAL DRUG ADMINISTRATION; MOTOR DYSFUNCTION; MYDRIASIS; NEUROSURGERY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; THALAMOTOMY;

EID: 0029852923     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-199603440-00010     Document Type: Review

References (75)

1. Redfern RM. History of stereotactic neurosurgery for Parkinson's disease. Br J Neurosurg 1989;3:271-304
2. Kelly PJ. Pallidotomy in Parkinson's disease. Neurosurgery 1995;36:1154-1157
3. Tasker RR. Tremor of parkinsonism and stereotactic thalamotomy. Mayo Clin Proc 1987;62:736-739
4. Yahr MD. Parkinsonism. In: Rowland LP, ed. Merritt's textbook of neurology. Philadelphia: Lea & Febiger, 1989:658-671
5. Quinn N. Parkinsonism - recognition and differential diagnosis. Brit Med J 1995; 310:145-150
6. Harris ZL, Takahashi Y, Miyajima H, et al. Aceruloplasminemia: molecular charac terization of this disorder of iron metabolism. Proc Natl Acad Sci USA 1995;92: 2539-2543
7. Heikkila RE, Manzino L, Cabbat FS. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469
8. McDowell F, Cedarbaum J. The extrapyramidal system and disorders of movement. In: Joynt R, ed. Clinical neurology. Philadelphia: J.B. Lippincott, 1991:19-48
9. Wichmann T, DeLong MR. Pathophysiology of parkinsonian motor abnormalities. Adv Neurol 1993;60:53-61
10. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16:439-444
11. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
12. Koller WC. How accurately can Parkinson's disease be diagnosed. Neurology 1992; 42(Suppl):6-16
13. Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonian plus syndrome. Neurol Clin 1992;10(Suppl):341-359
14. Quinn N. Drug treatment of Parkinson's disease. Brit Med J 1995;310:575-579
15. Koller W, Silver D, Lieberman A. An algorithm for the management of Parkinson's disease, a supplement of the American Academy of Neurology. Neurology 1994; 44(Suppl 10):S1-S52
16. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson's disease. Neurology 1981;31:125-131
17. Rajput AN, Rozdilsky B, Rajput A. Levodopa efficacy and pathological basis of parkinson syndrome. Clin Neuropharmacol 1990;13:553-558
18. Hoehn NM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10(Suppl 2):331-339
19. Martz DG, Schreibmen DI, Matjasko MJ. Neurological diseases. In: Katz J, Benumof JL, Kadis LB, ed. Anesthesia in uncommon disorders. Philadelphia: W.B. Saunders, 1990:563-564
20. Stoelting RK, Dierdorf SF. Diseases of the nervous system. In: Stoelting RK, ed. Anesthesia and coexisting disease. New York: Churchill-Livingstone, 1993:209-211
21. Birkmayer W, Knoll J, Riederer P. Improvement of life expectancy due to L-deprenyl in Parkinson's disease: a long-term study. J Neural Transm 1985;65:113-127
22. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
23. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371
24. Myllyla VV, Sotaniemi KA, Vuorinen JA. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42:339-343
25. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1992;42(Suppl 4):13-26
26. Rinne JO. Nigral degeneration in Parkinson's disease in relation to clinical features. Acta Neurol 1991;316(Suppl):87-90
27. Salo PT, Tatton WG. Deprenyl reduced the death of motor neurons caused by axotoms. J Neurosci Res 1992;31:394-400
28. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-672
29. Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 1967;17:124-136
30. Horrocks PM, Vicary DJ, Rees JD, et al. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973;36:936-941
31. Schwab RS, Poskanzer DC, England AC, et al. Amantadine in Parkinson's disease. JAMA 1972;222:792-795
32. Kurlan R. International symposium on early dopamine agonist therapy of Parkinson's disease. Arch Neurol 1988;45:204-208
33. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(Suppl 3):50-54
34. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a five-year follow-up. Neurology 1987;37:826-828
35. Lieberman A. Combination therapy of Parkinson's disease. Neurology 1993;443: 2725-2726
36. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-761
37. Leitinen LV, Bergenheim AT, Hariz MI. Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact Funct Neurosurg 1992;58(1-4):14-21
38. Leitinen LV. Pallidotomy for Parkinson's disease. Neurosurg Clin North Am 1995; 6:113-125
39. Meyers R. Surgical interruption of the pallidofungal fibers. Its effects on the syndrome of paralysis agitans and technical considerations in its applications. NY State J Med 1942;42:317-325
40. Cooper IS. The neurosurgical alleviation of Parkinsonism. Springfield: Charles C Thomas, 1956
41. Hassler R, Riechert, T. Indikationen and lokalisations-methode der gezielten Hirnoperationen. Nervenarzt 1954;25:441-447
42. Leitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurgery 1992;76:53-61
43. Iacono RP, Shima F, Lonser RR, et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease. Neurosurgery 1995;36:1118-1127
44. Iacono RP, Lonser RR, Mandybur G, et al. Stereotactic pallidotomy results for Parkinson's disease exceed those of fetal graft. Am Surg 1994;60:777-782
45. Bakay RAE. Central nervous system grafting: animal and clinical results. Stereotact Funct Neurosurg 1992;58:67-78
46. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84:203-214
47. Boyer KL, Bakay RAE. The history, theory, and present status of brain transplantation. Neurosurg Clin North Am 1995;6:113-125
48. Caparros-Lefebvre D, Blond S, Vermersch, et al. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:268-273
49. Burchiel KJ. Thalamotomy for movement disorders. Neurosurg Clin North Am 1995;6:55-71
50. Lozano A, Hutchison W, Kiss Z, et al. Methods for microelectrode-guided posteroventral pallidotomy. J Neurosurg 1996;84:194-202
51. Gildenberg PP. Management of movement disorders - an overview. Neurosurg Clin North Am 1995;6:43-53
52. Parent AG, Tasker RR, Dostrovski JO. Tremor reduction by microinjection of lidocaine during Stereotactic neurosurgery. Acta Neurochir (Wien) 1993;58(Suppl): 45-47
53. Dostrovski JO, Sher GD, Davis KD, et al. Microinjection of lidocaine in human thalamus: a useful tool in Stereotactic surgery. Stereotactic Funct Neurosurgery 1993;60:168-174
54. Burchiel KJ. Thalamotomy for movement disorders. Neurosurg Clin North Am 1995;6:55-71
55. Golbe LI, Langston GW, Shoulsten I. Selegiline in Parkinson's disease. Drugs 1990; 39:646
56. Zornberg GI, Bodkin JA, Colon BM. Severe adverse interaction between pethidine and selegiline. Lancet 1991;337:246
57. Avorn J, Gurwictz JH, Bohrn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995;274:1780-1782
58. Stahle L, Collin AK, Ungerstedt U. Effects of halothane anaesthesia on extracellular levels of dopamine, dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxy- indoleacetic acid in rat striatum: a microdialysis study. Naunyn-Schmied Arch Pharmacol 1990;342:136-140
59. El-Maghrabi EA, Eckenhoff RG. Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics. Anesthesiology 1993;78:750-756
60. Mantz TJ, Varlet C, Lecharny J-B, et al. Effects of volatile anesthetics, thiopental, and ketamine on spontaneous and depolarization-evoked dopamine release from striatal synaptosomes in rat. Anesthesiology 1994;80:352-364
61. Muravchick S, Smith DS. Parkinsonian symptoms during emergence from general anesthesia. Anesthesiology 1995;82:305-307
62. Kim YC, Cho MS, Kim SS, et al. Profound hypotension immediately following insertion of methyl methacrylate during bipolar endoprosthesis in a patient with long-term levodopa-treated paralysis agitans. J Korean Med Sci 1995;10:31-35
63. Reed AP, Han DG. Intraoperative exacerbation of Parkinson's disease. Anesth Analg 1992;75:850-853
64. Stone DJ, Difazio CA. Sedation for patients with Parkinson's disease undergoing ophthalmology surgery. Anesthesiology 1988;68:821
65. Eastdown JL, Tessler M, Jeffrey M. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure. Can J Anesth 1995;42:344-347
66. Backus WW, Ward RR, Vitkun SA, et al. Postextubation laryngeal spasm in an unanesthetized patient with Parkinson's disease. J Clin Anesth 1991;3:314-316
67. Ngai SH. Parkinsonism, levodopa and anesthesia. Anesthesiology 1972;3:340-344
68. Gravelee GP. Succinylcholine induced hyperkalemia in a patient with Parkinson's disease. Anesth Analg 1980;59:444-446
69. Munzi DA, Black S, Cucchiara RF. The lack of effect of succinylcholine on serum potassium in patients with Parkinson's disease. Anesthesiology 1989;71:322
70. Weinger MS, Smith NT, Blasco TA, Koob GF. Brain sites mediating opiate-induced muscle rigidity in the rat: methylnaloxonium mapping study. Brain Res 1991;544: 181-190
71. Loh HH, Brase DA, Sampath-Khan S, et al. β-Endorphin in vitro inhibition of striatal dopamine release. Nature 1976;264:567-568
72. Mets B. Acute dystonia after alfentanil in untreated Parkinson's disease. Anesth Analg 1991;72:557-558
73. Korczyn AB. Autonomic nervous system disturbances in Parkinson's disease. Adv Neurol 1990;53:463
74. Golden WE, Lavender RC, Metzen WS. Acute postoperative confusion and hallucinations in Parkinson's disease. Ann Intern Med 1989;111:218
75. Anderson BJ, Marks PV, Futter ME. Propofol-contrasting effects in movement disorders. Br J Neurosurg 1994;8:387-388